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Hereditary breast and ovarian cancer (HBOC) is caused by a mutation in the
BRCA1 or BRCA2 genes. Women with a BRCA1/2 mutation are at increased risks
for breast and ovarian cancer and often develop cancer at an earlier age than the
general population. However, some women with a BRCA1/2 mutation do not
develop breast or ovarian cancer under the age of 50 years. There have been no
specific studies on BRCA positive women with no cancer prior to age 50, therefore
this study sought to investigate factors within these women with no cancer under
age 50 with respect to reproductive risk factors, BMI, tumor pathology, screening
history, risk-reducing surgeries, and family history. 241 women were diagnosed
with cancer prior to age 50, 92 with cancer at age 50 or older, and 20 women were
over age 50 with no cancer. Data were stratified based on BRCA1 and BRCA2
mutation status. Within the cohorts we investigated differences between women
who developed cancer prior to age 50 and those who developed cancer at age 50
or older. We also investigated the differences between women who developed
cancer at age 50 or older and those who were age 50 or older with no cancer. Of
the 92 women with a BRCA1/2 mutation who developed cancer at age 50 or older,
46 developed ovarian cancer first, 45 developed breast cancer, and one had breast
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and ovarian cancer diagnosed synchronously. BRCA2 carriers diagnosed age 50
or older were more likely to have ER/PR negative breast tumors when compared to
BRCA2 carriers who were diagnosed before age 50. This is consistent with one
other study that has been performed. Ashkenazi Jewish women with a BRCA1
mutation were more likely to be diagnosed age 50 or older than other ethnicities.
Hispanic women with a BRCA2 mutation were more likely to be diagnosed prior to
age 50 when compared to other ethnicities. No differences in reproductive factors
or BMI were observed. Further characterization of BRCA positive women with no
cancer prior to age 50 may aid in finding factors important in the development of
breast or ovarian cancer.
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BACKGROUND
INTRODUCTION
Hereditary breast and ovarian cancer (HBOC) is a hereditary cancer
syndrome caused by mutations in the BRCA1 and BRCA2 genes. HBOC has an
autosomal dominant mode of inheritance and a high penetrance in mutation
carriers. Women with a BRCA1 or BRCA2 mutation are more likely to have an
HBOC-related cancer, such as breast or ovarian, and may be diagnosed at a
younger age than the general population. Although individuals with this syndrome
are at the greatest risk of developing breast or ovarian cancer, other cancers, such
as prostate and pancreatic, are also associated with HBOC.
BRCA1 was first cloned in 1994, followed by BRCA2 in 1995 (1). BRCA2
consists of 3,418 amino acids and, while little is known about its function, it is known
to be involved in homologous recombination (1). BRCA1 is 1,863 amino acids and
plays a role in DNA repair, protein ubiquitinylation, chromatin remodeling, and cellcycle-checkpoint control (1). Both of these genes play a role in preventing cancer
from developing, specifically in the breasts and ovaries. A mutation in one of these
two genes leads to an increased risk of breast and ovarian cancer.
The median age of ovarian cancer diagnosis in the general population is 63
years of age (2). Women with a BRCA1 or BRCA2 mutation often have a younger
age at diagnosis than the general population. The average age of ovarian cancer
diagnosis in women with a BRCA1 mutation is 52.6 years and is 58.8 years in those
with a BRCA2 mutation (3). The lifetime chance for a woman in the general

population to develop ovarian cancer is 1.4% (2). Individuals with a BRCA1 or
BRCA2 mutation have a significantly increased chance to develop ovarian cancer
with BRCA2 mutation carriers having a 27% risk for ovarian cancer by age 70 (4).
BRCA1 carriers have an estimated ovarian cancer risk of 11-42% by age 60 (5).
According to Surveillance, Epidemiology, and End Results (SEER) data,
women in the general population have a 12.08% chance to develop breast cancer
during their lifetime and the average age at diagnosis is 61 years of age (2).
Estimates for female breast cancer in BRCA carriers are that 90% of BRCA1 carrier
women will develop breast cancer and 41% of BRCA2 carrier women will develop
breast cancer (3). In addition to having higher lifetime risks of breast cancer,
women with a BRCA1 or BRCA2 mutation are often diagnosed at significantly
younger ages than the general population.
A meta-analysis of 22 studies unselected for family history showed that by
age 50, it was estimated that approximately 40% of BRCA1 carriers would develop
breast cancer and that approximately 12% would develop ovarian cancer (6). In
BRCA2 carriers it was estimated that approximately 15% would develop breast
cancer by age 50 and approximately 3% would develop ovarian cancer by age 50.
A study of 676 Ashkenazi Jewish families and 1,272 families of other ethnicities in
the US showed that the cumulative risk to age 50 for BRCA1 carriers was 28% (CI
24-34) for breast cancer and 13% (CI 9.7-17) for ovarian cancer (6). The
cumulative risks for BRCA2 carriers were 23% (CI 19-29) for breast cancer and 4%
(CI 2.2-6.2) for ovarian cancer by age 50 (6). These two studies differ in their
breast cancer risk estimates among BRCA1 and BRCA2 carriers (40% vs. 28% for
2

BRCA1 and 15% vs. 23% for BRCA2), however the ovarian cancer risk estimates
are quite similar (12% vs. 13% for BRCA1 and 3% vs. 4% for BRCA2).
There have been many studies investigating breast and ovarian cancer risk
factors in women with a BRCA1 or BRCA2 mutation, however many of these
studies have focused on women with early-onset breast or ovarian cancer. There is
very limited information about these factors in women with a later-onset of breast or
ovarian cancer or in older women who have not developed breast or ovarian
cancer. There may be factors that influence the chance that a woman with a
BRCA1 or BRCA2 mutation does not develop breast cancer at a younger age. To
our knowledge, there have been no studies performed to identify factors in BRCA
positive women with later-onset (≥50 years old) breast or ovarian cancer and
compare the factors to women who developed breast or ovarian cancer at an earlier
age (<50 years old).

REPRODUCTIVE RISK FACTORS
In addition to BRCA mutation status, there are other risk factors known to
influence whether or not a woman will develop breast or ovarian cancer. Certain
reproductive factors can increase risk or play a protective role in whether or not a
woman develops breast or ovarian cancer. These factors include parity, age at first
full-term pregnancy, age of menarche, age at menopause, breastfeeding, oral
contraceptive use, and hormone replacement therapy use.
Later age of menarche has been associated with a decreased risk of breast
cancer in the general population. Early menarche may induce an early proliferation
3

of mammary gland cells through early exposure to high hormonal levels causing an
increased risk of breast cancer (7), therefore early menarche (prior to age 12) is
associated with a higher lifetime risk of breast cancer in the general population (8).
One study found a later age of menarche in BRCA1 mutation carriers was
associated with a decreased breast cancer risk, however no protective effect was
observed in BRCA2 mutation carriers (9). Another study showed no association
with age at menarche and breast cancer risk in BRCA1 or BRCA2 mutation
carriers(10).
Ovarian cancer risk is decreased among women with a later age of
menarche. Among BRCA1 and BRCA2 carriers, there has not been any significant
evidence that age at menarche is positively or negatively associated with ovarian
cancer risk (11).
Women in the general population have an increased risk of breast cancer if
they undergo menopause at a later age. This is likely due to the increased duration
and amount of estrogen and progesterone (7). A study of BRCA1 and BRCA2
mutation carriers found no overall association with menopause and breast cancer
risk (10). Early menopause has also been found to be protective against ovarian
cancer. One particular study found early menopause to confer an odds ratio of 0.6
when women who underwent menopause prior to age 45 were compared to those
who underwent menopause after age 45 (12). There have been no studies that
explore the relationship between age at menopause and ovarian cancer in women
with a BRCA1 or BRCA2 mutation.
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Early age at first full-term pregnancy is associated with a decreased risk for
breast cancer in the general population. Women under age 18 at their first full-term
pregnancy have only 40% of the breast cancer rates of women with no pregnancies
(13). In addition, late pregnancies may increase breast cancer risk for women in the
general population. Women with their first full-term pregnancy occurring after age
35 showed a 20% higher risk of developing breast cancer than those who were
nulliparous (13). The role of pregnancy in the etiology of BRCA-breast cancer is not
clear. In women with a BRCA1 or BRCA2 mutation, early full-term birth was not
found to be protective against breast cancer (14), suggesting that the factors
playing a role in the general population may not be applicable to women who are
genetically predisposed to developing breast cancer. In BRCA2 carriers, first
childbirth at later ages has been associated with an increased risk for breast cancer
when compared to those with their first childbirth prior to age 20 (11). In BRCA1
mutation carriers, first full-term pregnancy after age 30 has been associated with a
reduction of breast cancer risk compared to those whose first full-term pregnancy
occurred before age 20 (15). As this is in contradiction to findings in the general
population, this further suggests that factors playing a role in the general population
may not be applicable to BRCA carriers. In the general population, later age at first
birth is associated with a reduced risk of ovarian cancer. This same association has
been seen in both BRCA1 and BRCA2 carriers (16).
An increasing number of full-term pregnancies has been associated with a
decreased risk for breast cancer in the general population. Some studies suggest
that this may be due to decreased levels of estrogen and progesterone, increased
5

levels of sex hormone-binding globulin, and pregnancy-induced differentiation of
breast tissue (12). A study performed in a population of BRCA1 and BRCA2
mutation carriers found a decreased risk of breast cancer as the number of full-term
pregnancies increased (9), however the results were not statistically significant.
Another study found no statistically significant difference in the risk of breast cancer
between parous and nulliparous women (15). For carriers and noncarriers of a
BRCA1 or BRCA2 mutation, women who have had four or more full-term
pregnancies had a near fifty percent reduction of breast cancer risk when compared
to nulliparous women (9). This protective effect was mainly limited to women who
had their first full-term pregnancy prior to age 25. Among women over age 40 with
a BRCA mutation who have had a full-term pregnancy, an increasing number of fullterm pregnancies was associated with a 14% decrease in the breast cancer risk for
each pregnancy (15).
Women in the general population have a decreased ovarian cancer risk as
parity increases. One study found that parity was associated with a decreased risk
of ovarian cancer in BRCA1 carriers and an increased risk of ovarian cancer in
BRCA2 carriers (17). Another study identified the same protective effects of parity
in BRCA1 carriers but did not identify any significant association between parity and
ovarian cancer risks in BRCA2 carriers (16).
A longer duration of breastfeeding has been found to decrease the breast
cancer risk in the general population. Several theories have been proposed to
explain this observation, including postponed resumption of ovulatory menstrual
cycles, breast tissue differentiation, decreased estrogen levels, and excretion of
6

carcinogens from the breast ductal tissue (9). A longer duration of breast-feeding
has not been found to have a decreased risk of breast cancer in BRCA2 mutation
carriers (9, 15, 18). While some studies have shown breast-feeding to have no
effect in BRCA1 mutation carriers (9, 15), one study found that women with a
BRCA1 mutation who breast-fed for more than one year were 45% less likely to
have breast cancer than those who had never breast fed (13).
Breastfeeding among the general population confers a decreased risk of
developing ovarian cancer. In one study of women with a BRCA1 mutation, breastfeeding was shown to be protective against ovarian cancer (17), however other
studies have found no association among BRCA1 or BRCA2 carriers’ ovarian
cancer risk and breastfeeding (11).
Studies on the use of oral contraceptives and its influence on breast cancer
have not been conclusive. Some studies show that oral contraceptive use is not
associated with breast cancer risk in the general population or in BRCA1 or BRCA2
mutation carriers (9). In a meta-analysis, women currently using combined oral
contraceptives or women who had used them in the past 10 years were found to
have a slightly increased risk of breast cancer (19). They found no evidence of an
increased risk of breast cancer diagnosed 10 or more years after discontinuing use.
Women who had ever used oral contraceptives had a relative risk of 1.07 of
developing breast cancer when compared to women who had never used oral
contraceptives (19). One study showed a decreased risk of breast cancer among
BRCA1 mutation carriers, although the results were not statistically significant (9).
Another study found that BRCA1 mutation carriers who used oral contraceptives for
7

5 years or longer had an increased risk for breast cancer when compared to BRCA1
carriers who did not use oral contraceptives (odds ratio 1.33) (20). However, oral
contraceptive use after age 30 was not likely to increase the risk of breast cancer
among BRCA1 mutation carriers (20). This study did not find an association among
BRCA2 carriers and oral contraceptive use, although the sample size for this group
was small (20). Given that numerous studies have been done on this topic and
there are contradictions between them, there is currently no real consensus on the
effect of oral contraceptives on breast cancer risk. However, oral contraceptive use
has consistently been found to reduce the risk of ovarian cancer in the general
population as well as in women with a BRCA1 or BRCA2 mutation (17).
Hormone replacement therapy (HRT) has been found to increase the risk of
breast cancer in the general population and the risk of breast cancer increases with
increasing duration of HRT (21). A study of BRCA1 mutation carriers did not find
that HRT was associated with an increased risk of breast cancer (22). This study
also did not find an association between the duration of HRT use and the risk of
breast cancer among women with a BRCA1 mutation. An increased risk of ovarian
cancer has been associated with HRT use in the general population, however there
have been some conflicting studies and the ovarian cancer and HRT relationship is
not quite clear in the literature (23-25). There was no association between HRT and
ovarian cancer risk seen in a study looking at BRCA positive women (26).
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BODY MASS INDEX (BMI)
Body mass index (BMI) is calculated from a person’s height and weight. A
higher BMI has been associated with a decreased risk of breast cancer prior to
menopause and is minimally associated with an increased risk for breast cancer
after menopause (27). The increased risk for breast cancer in heavier
postmenopausal women may be attributed to higher levels of estrogen in the
woman since the primary source of estrogen after menopause is the conversion of
androstenedione to estrone in adipose tissue (28). When comparing
postmenopausal women who have the highest BMI to postmenopausal women who
have the lowest BMI, studies report a relative risk of breast cancer of 1.5-2.0 (28).
In women with a BRCA mutation, increases or decreases in body weight during
early adult life may be more important in determining the risk for breast cancer than
current weight or BMI (29).
The association of ovarian cancer and BMI has not been consistent. Some
studies show that ovarian cancer risk increases in the general population as BMI
increases (30, 31). In a meta-analysis of 28 studies, the risk of epithelial ovarian
cancer among obese women was estimated to be 30% higher than women with a
normal BMI and women considered overweight had a 16% increased risk of ovarian
cancer when compared to women with a normal BMI (30). The association
between ovarian cancer and BMI may depend on a woman’s menopausal status.
BMI has been associated with an approximately 2-fold increased ovarian cancer
risk among premenopausal women (age <50 years), however among
postmenopausal women there was no significant association between BMI and
9

ovarian cancer (32). There have been no studies, to our knowledge, looking at the
association between BMI and ovarian cancer in women with a BRCA1/2 mutation.
However, some studies have shown that in women who have a family history of
ovarian cancer, there is no association between BMI and ovarian cancer (31).

SCREENING MODALITIES AND FREQUENCIES
There have been specific recommendations made for women who have a
BRCA1 or BRCA2 mutation in order to screen for breast and ovarian cancer. These
recommendations are in place to help detect these types of cancer at a stage that
is, ideally, earlier and more treatable. The National Comprehensive Cancer
Network (NCCN) has developed a set of practice guidelines for cancer screening in
women with a BRCA1 or BRCA2 mutation. The 2009 guidelines include breast selfexamination monthly beginning at age 18 as well as clinical breast exams
semiannually beginning at age 25. Annual mammograms and breast MRI should
begin at age 25. To screen for ovarian cancer, the NCCN guidelines recommend
concurrent transvaginal ultrasound and CA-125 blood test every 6 months
beginning at age 35 or 5-10 years prior to the earliest age of ovarian cancer onset in
the family. Ovarian cancer screening has not been shown to be effective, therefore
it is recommended that women with an increased risk to develop ovarian cancer
undergo risk-reducing bilateral salpingo-oophorectomy (33).
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CHEMOPREVENTION
Chemopreventive agents, such as tamoxifen, may be offered to women at an
increased risk of breast cancer based on personal history, family history, or BRCA
mutation status. Tamoxifen targets the estrogen receptor (ER) in breast cells,
therefore tamoxifen may not have as great an effect on ER negative breast cancers.
Given that many BRCA1-related breast cancers tend to be ER negative, tamoxifen
may not significantly reduce breast cancer risk among BRCA1 mutation carriers.
Tamoxifen use does not have an effect on ovarian cancer risk (34).
Women in the general population receive protection against breast cancer
when taking tamoxifen. Women who took tamoxifen for seven years had a rate of
breast cancer of 24.8 per 1000 as compared to 42.5 per 1000 women in the
placebo group (35).
While no large studies to date have assessed the effect of tamoxifen on
BRCA1 and BRCA2 carriers that do not have a history of breast cancer, studies
have shown a decreased risk of contralateral breast cancer in BRCA1 and BRCA2
mutation carriers (36). The risk of contralateral breast cancer was decreased by
greater than 50% in BRCA1/2 mutation carriers when tamoxifen was used as
treatment for their initial breast cancer diagnosis (36). Given this data, it is
reasonable to assume that tamoxifen use in women with a BRCA1 or BRCA2
mutation who have never had a breast cancer diagnosis would experience a
decreased risk of developing breast cancer, however no large studies have been
reported. One study observed women with no previous breast cancer diagnosis
and found that of the 8 women with a BRCA1 mutation who developed breast
11

cancer, 5 were taking Tamoxifen and 3 were in the placebo group (risk ratio 1.67)
(34). In this same study, of 11 women with BRCA2 mutations who developed
breast cancer, 3 were taking tamoxifen and 8 were in the placebo group (risk ratio
0.38) (34). Given the small sample size, general inferences cannot be made,
however it appears that tamoxifen use may be effective in BRCA2 mutation carriers,
but not in those with a BRCA1 mutation.

RISK-REDUCING SURGERIES
Bilateral mastectomy and bilateral salpingo-oophorectomy (BSO) are often
recommended to women with a BRCA1 or BRCA2 mutation to decrease the chance
of developing breast and/or ovarian cancer. Mastectomy reduces the risk of breast
cancer while BSO reduces the risk of both breast and ovarian cancer (37-42). The
hypothesis for why BSO affects breast cancer risk is that estrogen deprivation
reduces the risk of breast cancer (37).
Prophylactic BSO decreases the chance for ovarian cancer to develop in
women with a BRCA1 or BRCA2 mutation. Prospective studies identified a reduced
risk of ovarian cancer in BRCA1 carriers (39). While protection was suggested for
BRCA2-associated ovarian cancer in this study, it did not reach statistical
significance, likely due to the small number of BRCA2 carrier (39). A meta-analysis
of 10 studies found an 80% reduction of ovarian cancer after BSO (42). Another
study that was performed showed a 96% reduction of ovarian cancer risk after BSO
(43).
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BSO has been associated with a 57% reduction in breast cancer risk in
BRCA1 carriers and a 46% risk reduction in BRCA2 carriers (37). Another study
showed a hazard ratio of 0.53 for breast cancer risk in BRCA1 mutation carriers
who had undergone prophylactic BSO when compared to BRCA1 carriers who had
not undergone the surgery (38). While oophorectomy at a premenopausal age
decreases the risk for breast cancer throughout a woman’s lifetime, the effect
appears greater for breast cancers diagnosed before age 50 (37-39). A prospective
study found that prophylactic BSO was associated with a significant decreased risk
of breast cancer in BRCA2 mutation carriers (39). Other studies have shown an
approximately 50% risk reduction of developing breast cancer following a
premenopausal BSO (42, 43).
Bilateral mastectomy reduces a woman’s risk of breast cancer by
approximately 90% if she carries a BRCA1 or BRCA2 mutation (41). In a group of
76 women with a BRCA1 or BRCA2 mutation who chose to undergo prophylactic
mastectomy, none of them developed breast cancer whereas in a group of 63
women with a BRCA1 or BRCA2 mutation who did not undergo the surgery, 8
women developed breast cancer (40). Another study showed that 1.9% of
BRCA1/2 carriers were diagnosed with breast cancer after prophylactic mastectomy
whereas 48.7% of controls were diagnosed with breast cancer (41).
Women may choose to undergo prophylactic mastectomy and/or BSO in
order to greatly reduce their chances of developing breast and/or ovarian cancer,
however there are many psychosocial concerns that may also affect whether or not
a woman chooses to have the surgery done. In addition, even if a woman chooses
13

to undergo these procedures, there is still a risk for her to develop breast and/or
ovarian cancer (primary peritoneal cancer) as the procedures do not confer a 100%
reduction of cancer risk.

HORMONE RECEPTOR STATUS
Hormone receptor status has been found to vary among breast cancers and
can also have prognostic factors for the cancer. Estrogen and progesterone are
important in the development and progression of breast cancer. Estrogen receptor
(ER) and progesterone receptor (PR) status have been found to be the most
important predictors of endocrine therapy response (44). Approximately 65% of
female breast cancers are ER positive and 50% are PR positive (45). ER and PR
status tend to be positive more often in patients whose tumor developed at an older
age (45). Tumors that are ER and PR positive tend to have a better response to
endocrine therapies and have a better prognosis when compared to women with ER
and PR negative tumors (46).
Studies have found that women with a BRCA1 mutation are more likely to
have ER/PR negative breast cancers than women with a BRCA2 mutation or
women with no BRCA mutation (47-49). A study by Atchley et al (47) found that
women with triple-negative breast cancer who were BRCA2 mutation carriers were
diagnosed at a later age than BRCA1 mutation carriers and noncarriers.
Her-2/neu status is another pathological characteristic found in breast
cancer. Her-2/neu is a proto-oncogene that has been identified in up to 34% of
breast cancers (50). The amplification and protein overexpression of Her-2/neu is
14

associated with an adverse outcome in breast cancer (50). There have been
inconsistent findings when identifying the relationship between Her-2/neu status and
BRCA1 and BRCA2 mutations. Some studies have found that Her-2/neu status
among BRCA1 mutation carriers does not differ when compared to noncarriers (47),
however other studies have reported that BRCA1 status is associated with Her2/neu-negative breast cancers (51).
Many studies have looked at early-onset breast cancer and the association
with ER, PR, and Her-2/neu status. We could not find any studies that look at this
association between women with a BRCA1 or BRCA2 mutation who were
diagnosed with breast cancer at a later age. It is largely unknown whether or not
there is a difference in ER, PR, and Her-2/neu status when comparing women with
early- vs. late-onset breast cancer.

ETHNICITY
The incidence of breast cancer in the general population varies by
race/ethnicity. White women have the highest breast cancer incidence (141.1 in
100,000 females) followed by African Americans (119.4), Asian Americans/Pacific
Islanders (96.6) and Hispanics/Latinas (89.9) (52). American Indians/Alaska
Natives have the lowest incidence of breast cancer (54.8) (52). White women in the
United States are at a higher risk for developing ovarian cancer (13.1 in 100,000)
than American Indians (10.2), Hispanics (9.4), African Americans (9.0) and
Asian/Pacific Islanders (8.0) (53).
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Given that white women are at the highest risk to develop breast and ovarian
cancer, it is reasonable to presume that a white woman with a BRCA1 or BRCA2
mutation may be at higher risk to develop breast and/or ovarian cancer than a
Hispanic/Latina with a BRCA1/2 mutation. In individuals with a breast cancer
diagnosis, BRCA1 and BRCA2 mutation rates across ethnic groups are fairly similar
with a rate of 1-4% for each gene (54). Therefore, the differences in prevalence of
breast and ovarian cancer among different ethnic/racial populations cannot be
explained exclusively by the rate of mutations in the BRCA1 and BRCA2 genes in
those populations. There are likely other genetic factors within racial groups that
influence a woman’s risk of developing breast or ovarian cancer.

FAMILY HISTORY
A family history of breast or ovarian cancer increases the risk for a woman to
develop these types of cancers. One study showed that having two or more firstdegree female relatives with breast cancer is associated with an increased risk to
develop ovarian cancer (OR 9.5; CI 1.0-87.0), however there were very few cases
and this may be due to chance (55). In a meta-analysis of women with a family
history of ovarian cancer, the relative risk to first-degree relatives was 3.1 (56).
Sisters of a woman with ovarian cancer had a higher relative risk (3.8) of ovarian
cancers than mothers of cases (1.1) (56). Daughters of cases had the highest
relative risk of ovarian cancer (6.0) (56).
A family history of breast cancer confers a greater risk of breast cancer in an
individual. In a meta-analysis of 74 studies of breast cancer risk and family history,
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it was found that a woman with any first-degree relative affected with breast cancer
has a relative risk of 2.1 when compared to women with no family history of breast
cancer (57). A woman with a mother diagnosed with breast cancer has a 2.0
relative risk to develop breast cancer and a woman with a sister diagnosed with
breast cancer has a 2.3 relative risk (57). Women with a second-degree relative
diagnosed with breast cancer have a relative risk of 1.5 to develop the same type of
cancer (57). All of these risks were increased if the relative was diagnosed at a
younger age (57).
One study found that the age of breast cancer onset in a woman with a
BRCA mutation and a family history of breast cancer can be predicted to a small
extent by the youngest age of diagnosis within the family and the mean age of
diagnosis in the family (58). This effect was slightly significant in BRCA2 carriers
but not in BRCA1 carriers. Based on this study, they concluded that it appears that
an unaffected carrier may have an earlier age at diagnosis if the youngest diagnosis
in the family is less than 35 years when compared to families were all cases were
over age 35 (58). In a study of Polish women with a BRCA1 mutation, they found
that relatives of women diagnosed with breast cancer had a higher risk of breast
cancer than relatives of women diagnosed with ovarian cancer (OR=1.7; p=0.03)
(59). Some researchers theorize that there may be other modifier genes
contributing to a greater cancer risk within certain families with a BRCA mutation
(60). While the effect of family history on BRCA mutation carriers’ cancer risk does
not seem to be entirely clear, it does seem to play a role.
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In conclusion, there are many factors that play a role in the development of
breast and/or ovarian cancer in the general population. These factors have not
been investigated in the development of later-onset breast or ovarian cancer among
women with a BRCA1 or BRCA2 mutation. In addition, these factors have not been
explored among women with a BRCA1 or BRCA2 mutation living at older ages with
no history of breast or ovarian cancer. In this study, we attempt to investigate
reproductive risk factors, hormone receptor status, screening frequencies and
modalities, risk-reducing surgeries, as well as family history among women with a
BRCA mutation who did not develop cancer before the age of 50 years and are
followed at MD Anderson Cancer Center.
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MATERIALS AND METHODS
Study Design
This study was a retrospective chart review of a select population of women with a
BRCA1 or BRCA2 mutation. The specific aims of this study were to 1) determine if
any factors influence whether a woman with a BRCA1 or BRCA2 mutation develops
breast or ovarian cancer at an early age (<50 years of age) or a later age (≥50
years) and to identify which factors are important and 2) determine if any factors
influence whether or not a woman with a BRCA1 or BRCA2 mutation develops
cancer and determine which factors are important. The factors observed in this
study include reproductive factors, BMI, risk-reducing surgeries, and family history.
Differences in these factors between women with a BRCA mutation who
developed breast or ovarian cancer under age 50 and women with a BRCA
mutation who developed breast or ovarian cancer at age 50 or older were
investigated. In addition, differences in these factors between women with a BRCA
mutation over age 50 with no cancer diagnosis and women with a BRCA mutation
who developed cancer at age 50 or older were investigated. The MD Anderson
Cancer Center electronic medical records (EMR) of this population were reviewed
and relevant information was extracted and analyzed to identify trends and
differences in the data. We hypothesized that there would be differences among
women who developed breast or ovarian cancer at age 50 or older, women who
developed breast or ovarian cancer prior to age 50, and women over age 50 who
had never developed breast or ovarian cancer.
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Study Approval
Approval for this study was granted by the University of Texas-Houston
Health Science Center and the Committee for the Protection of Human Subjects of
MD Anderson and the on September 1, 2009 and November 5, 2009, respectively.

Study Population
The study population consisted of 353 MD Anderson Cancer Center patients
with a BRCA1 or BRCA2 mutation. Of these women, 20 women are ≥50 years of
age and have never had a breast or ovarian cancer diagnosis. Ninety-two women
were diagnosed with breast or ovarian cancer ≥50 years of age. There were 241
MD Anderson Cancer Center patients with a BRCA1 or BRCA2 mutation who had a
breast or ovarian cancer develop prior to age 50. Myriad Genetics Laboratory in
Salt Lake City, Utah performed the genetic testing.

Ascertainment
Study subjects were ascertained through an IRB approved research
database at MD Anderson Cancer Center. The study population included patients
at MD Anderson between 2/1/1997 and 11/16/2009. A total of 434 patients were
identified as potential study participants and their fulfillment of the inclusion criteria
was confirmed during review of their medical records. Of the 434 patients, 81
participants were excluded because they did not meet the inclusion criteria for the
study. The following individuals were excluded from our data: men, individuals with
a variant of uncertain significance and no deleterious mutation, and individuals with
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no BRCA1 or BRCA2 mutation found. Women who had a variant of uncertain
significance identified along with a known deleterious BRCA1 or BRCA2 mutation
were included in our population. Women with ductal carcinoma in situ (DCIS) were
not included in our study unless they also had an invasive cancer and we recorded
their age at diagnosis at the time that they developed the invasive cancer.

Data Collection
The study population’s medical records at MD Anderson Cancer Center were
reviewed December 2009 through February 2010. The information extracted from
the medical records is presented in table 1.
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Table 1. Information Obtained through Medical Record Review
General Information
Date of birth
Ethnicity
Age of last contact with MD Anderson Cancer Center
BRCA mutation status
Age at breast or ovarian cancer diagnosis
Reproductive Risk Factor Information and BMI
Age at menarche
Age at menopause (if applicable)
Age at first full term pregnancy
Parity (prior to diagnosis)
Breastfeeding history
Hormone replacement therapy use
Oral contraceptive use
Chemopreventive use (Tamoxifen)
BMI (Based on height and weight at time of testing)
Screening History
Type of screening received (Mammography, Breast MRI, Clinical breast exam,
Transvaginal ultrasound, or CA-125 blood test)
Frequency of screening
Risk-Reducing Surgery
Type of surgery (Bilateral mastectomy or bilateral salpingo-oophorectomy)
Age at surgery
Tumor Pathology Information
ER and PR Status
Her2/neu status
Type of cancer
Family History Information
Number of first and second degree relatives with a breast or ovarian cancer
diagnosis
Age of cancer diagnosis in first and second degree relatives
Number of unaffected first and second degree relatives

Statistical Analysis
STATA 10.0, Microsoft Office Excel 2007, and Microsoft Office Access 2007
were used to analyze the data that was obtained from the MD Anderson electronic
medical records. Descriptive statistics were performed to summarize the content of
each variable for BRCA1 carriers with cancer under age 50, BRCA1 carriers with
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cancer over age 50, BRCA1 carriers with no cancer diagnosis, BRCA2 carriers with
cancer under age 50, BRCA2 carriers with cancer over age 50, and BRCA2 carriers
with no cancer diagnosis. All of these variables were analyzed to identify
differences based on mutations status and we compared women who developed
cancer at age 50 or older to women who developed cancer before age 50 and those
who had no cancer diagnosis. P-values less than 0.05 were considered to be
statistically significant.
We used contingency tests (eg. Pearson’s chi square) to compare
frequencies among our groups. T-tests were used to analyze normally distributed
continuous variables between the two groups and Mann-Whitney tests were used to
compare non-normally distributed continuous variables among the groups. We
performed four analyses on most variables and compared the differences between
the following cohorts as shown in figure 2 and 3. Women diagnosed with cancer at
or after age 50 were our referent group for all analyses. As shown in figure 2, we
analyzed the differences in BRCA1 or BRCA2 mutation carriers who developed
cancer before age 50 and those who developed cancer at age 50 or older. These
data were stratified by BRCA mutation status. As shown in figure 3, we analyzed
differences in women who developed cancer at age 50 or older and women who
had never developed cancer stratified on their BRCA mutation status.
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Figure 1. Analysis between women with cancer <
<50
50 and women with cancer ≥50
years of age
BRCA2
Positive
Women

Cancer ≥50

Cancer <50

(n=51)

(n=71)

Figure 2. Analysis between women with cancer ≥50
50 years of age and those with no
cancer
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RESULTS
The population for our study is shown in figure 2. BRCA1 and BRCA2
mutation carriers were analyzed separately for reproductive risk factors, tumor
characteristics, ethnicity, risk-reducing surgeries, and family history. There was one
woman with a BRCA1 and BRCA2 mutation. She was not included in the analysis
because the effect of having a mutation in both BRCA genes may impact the risk of
developing breast or ovarian cancer when compared to women who have a
mutation in only one of the genes.
Figure 3. Flowchart for study population
170 with cancer
<50

223 with BRCA1
mutation

41 with cancer ≥50

12 ≥50 with no
cancer

434 BRCA mutation
carriers in database
(2/1/199711/16/2009)

354 women eligible
for study

80 ineligible
patients

71 with cancer <50

130 with BRCA2
mutation

51 with cancer ≥50

1 with BRCA1 &
BRCA2 mutation
(not included in
study)

8 ≥50 with no
cancer

Average Age of Population
The average age at diagnosis was not statistically significant between
BRCA1 and BRCA2 women diagnosed prior to age 50. There was also no
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statistically significant difference in age at diagnosis between BRCA1 and BRCA2
women diagnosed at age 50 or older. No statistically significant difference was
found between the current average age of women with a BRCA1 or BRCA2
mutation who are over age 50 with no cancer diagnosis. The mean ages for these
groups, as well as p values for this analysis, are presented in tables 2-4.

Table 2. Age at Diagnosis (<50) based on BRCA mutation status
Cancer dx. <50
Mean Age (SD)
P-Value
BRCA1
38.87 (6.69)
0.3166
BRCA2
39.79 (5.92)

Table 3. Age at Diagnosis (≥50) based on BRCA mutation status
Mean Age (SD)
P-Value
Cancer dx. ≥50
BRCA1
57.68 (5.46)
0.2742
BRCA2
56.41 (5.55)

Table 4. Average Current Age based on BRCA mutation status
≥50 with no
Mean Age (SD)
P-Value
cancer dx.
BRCA1
59.5 (9.56)
0.5046
BRCA2
56.88 (6.31)

Type of Cancer First Diagnosed
There was a statistically significant difference (p<0.0001) between the type of
cancer diagnosed in women before age 50 and at age 50 or older in women with a
BRCA1 mutation. Results were similar in women with a BRCA2 mutation
(p<0.0001). Women who developed cancer prior to age 50 were more likely to
have breast cancer whereas those who developed cancer at age 50 or older were
more likely to have ovarian cancer as their first cancer diagnosis.
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The numbers and percentages of women with each type of cancer diagnosis
are shown in figures 4-5.

Figure 4: Type of cancer first diagnosed in BRCA1 mutation carriers, by age at
diagnosis
1
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1
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Breast &
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Figure 5: Type of cancer first diagnosed in BRCA2 mutation carriers, by age at
diagnosis
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REPRODUCTIVE FACTORS
Mean age Menarche
There was no difference in the mean age at menarche between women with
a BRCA1 or BRCA2 mutation who developed cancer prior to age 50 or those who
had never developed cancer when compared to women who developed cancer at
age 50 or older. The mean age at menarche as well as p-values are shown in
tables 5-6.

Table 5. Age at menarche based on cohort (BRCA1)
Mean (SD)
BRCA1
<50 w/ cancer
12.81 (1.59)
≥ 50 w/ cancer *
13.03 (1.78)
≥50 w/o cancer
12.18 (0.98)
* Referent Group

Table 6. Age at menarche based on cohort (BRCA2)
BRCA2
Mean (SD)
<50 w/ cancer
12.83 (1.31)
≥ 50 w/ cancer *
12.68 (1.27)
≥50 w/o cancer
13.13 (1.73)
* Referent Group

P-value
0.4522
0.1406

P-value
0.5455
0.3899

Mean age Menopause
Women with a BRCA1 or BRCA2 mutation diagnosed with cancer under age
50 underwent menopause at a statistically significant younger age than those
diagnosed with cancer at age 50 or older (p<0.0001 for BRCA1; p=0.0007 for
BRCA2). In addition, women with a BRCA1 mutation diagnosed with cancer at age
50 or older underwent menopause at a statistically significant older age than women
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with a BRCA1 mutation who had never had a cancer diagnosis (p=0.0312). Women
with a BRCA2 mutation diagnosed with cancer at age 50 or older had no statistically
significant difference from those never diagnosed with cancer (p=0.5204). Figure 6
shows the average age of menopause among the different cohorts.

Figure 6. Age at menopause based on cohort, by age at diagnosis
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43.75

44

≥50 w/ cancer
43.65

≥50 w/o cancer

42
40
BRCA1

BRCA2

Mean Age at First Full Term Pregnancy
There was no difference in the age at first full-term pregnancy between
women with a BRCA1 or BRCA2 mutation who developed cancer before age 50
when compared to those who developed cancer at age 50 or older. In addition,
there was no difference between BRCA1 or BRCA2 positive women who developed
cancer at age 50 or older when compared to women who had not developed
cancer. Mean age at first full term pregnancy and p-values are shown in tables 7-8.
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Table 7. Mean age at first full term pregnancy based on cohort (BRCA1)
BRCA1
Mean (SD)
P-value
<50 w/ cancer
24.82 (5.75)
0.1081
≥ 50 w/ cancer *
23.06 (3.93)
≥50 w/o cancer
24.89 (4.31)
0.2376
* Referent Group

Table 8. Mean age at first full term pregnancy based on cohort (BRCA2)
BRCA2
Mean (SD)
P-value
<50 w/ cancer
25.64 (5.66)
0.8075
≥ 50 w/ cancer *
25.35 (5.58)
≥50 w/o cancer
26.67 (6.66)
0.6999
* Referent Group

Parity
There was no difference in parity between women with a BRCA1 or BRCA2
mutation diagnosed with cancer over age 50 and those never diagnosed with
cancer. In addition, there was no statistically significant difference between women
with a BRCA1 or BRCA2 mutation who developed cancer prior to age 50 and those
who developed cancer at age 50 or older. The median parity and p-values for each
cohort are shown in tables 9-10.

Table 9. Median parity based on cohort (BRCA1)
Median (Range)
BRCA1 Group
<50 w/ cancer
2 (0-8)
≥50 w/ cancer *
2 (0-10)
≥50 w/o cancer
2 (0-4)
* Referent Group

Table 10. Median parity based on cohort (BRCA2)
BRCA2 Group
Median (Range)
<50 w/ cancer
2 (0-6)
≥50 w/ cancer *
2 (0-7)
≥50 w/o cancer
2.5 (0-4)
* Referent Group

P-value
0.0710
0.5962

P-value
0.0595
0.8546
30

When parity was broken into groups of 0, 1, 2, 3, or ≥4 children, there was no
statistically significant difference between any of the groups. The p-value for
BRCA1 positive women with cancer development prior to age 50 vs. those who
developed cancer at age 50 or older was 0.6839. When BRCA1 positive women
who developed cancer at age 50 or older were compared to those who had never
developed cancer, the p-value was 0.8508. When BRCA2 positive women who
developed cancer prior to age 50 were compared to those who did not develop
cancer until at age 50 or older, the p-value was 0.5886. BRCA2 positive women
who developed cancer at age 50 or older and those who had not developed cancer
did not differ significantly in respect to their parity group (p=0.8281).
There was no statistically significant difference between parous women and
non-parous women with a BRCA1 mutation who developed cancer at age 50 or
older when compared to those who developed cancer prior to age 50 (p=0.166) or
those who had not developed cancer (p=0.924). There was no difference between
parous and non-parous women with a BRCA2 mutation who developed cancer at
age 50 or older when compared to those who developed cancer prior to age 50
(p=0.664) and those who had not yet developed cancer (p=0.309).

Mean time breastfeeding (if parity >0)
There was no statistically significant difference between women with a
BRCA1 mutation who developed breast cancer prior to age 50 (p=0.3700) or had
never developed cancer (p=0.9218) when compared to those who had developed
cancer at age 50 or older. Women with a BRCA2 mutation who developed cancer
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prior to age 50 did not differ significantly from women who developed cancer at age
50 or older (p=0.0805). There was also no statistical difference in the median
breastfeeding time period when comparing BRCA2 mutation carriers who
developed cancer at age 50 or older to those who had never developed cancer
(0.6371). The median number of months of breastfeeding and p-values for each
cohort are presented in tables 11-12.

Table 11. Median months of breastfeeding based on cohort (BRCA1)
BRCA1 Group
Median (Range)
P-value
<50 w/ cancer
3 (0-44)
0.3700
≥50 w/ cancer *
1.5 (0-9)
≥50 w/o cancer
4 (0-10)
0.9218
* Referent Group
Table 12. Median months of breastfeeding based on cohort (BRCA2)
BRCA2 Group
Median (Range)
P-value
<50 w/ cancer
4 (0-24)
0.0805
≥50 w/ cancer *
3 (0-18)
≥50 w/o cancer
0 (0)
0.6371
* Referent Group
There was no difference between the cohorts when comparing whether or
not they had ever breastfed their children. The number of women who breastfed
their children and the p-values associated are shown in tables 13-14.

Table 13. Breastfeeding status based on cohort (BRCA1)
≥50 w/
<50 w/ cancer
cancer *
Breastfeeding
BRCA1

Yes
No
* Referent Group

n, (%)
Total n=10

n, (%)
Total n=48

P-value

6 (60)
4 (40)

34 (71)
14 (29)

0.501

≥50 w/out cancer
n, (%)
Total
n=3
2 (67)
1 (33)

P-value
0.835
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Table 14. Breastfeeding status based on cohort (BRCA2)
≥50 w/
<50 w/ cancer
cancer
*
Breastfeeding
BRCA2

Yes
No
* Referent Group

n, (%)
Total n=11

n, (%)
Total n=23

P-value

7 (64)
4 (36)

15 (65)
8 (35)

0.928

≥50 w/out cancer
n, (%)
Total
n=0
0 (0)
1 (100)

P-value
0.217

HRT and OCP Use
Oral contraceptive use did not affect the development of cancer among
BRCA1 or BRCA2 women who developed cancer at age 50 or older when
compared to those who developed cancer prior to age 50 or had never developed
cancer. The numbers and percentages of women who used oral contraceptives are
shown in tables 15-16.

Table 15. Oral Contraceptive use based on cohort (BRCA1)
≥50 w/
<50 w/ cancer
cancer
*
OCP Use
BRCA1

Yes
No
* Referent Group

n, (%)
Total n=33

n, (%)
Total n=151

P-value

25 (76)
8 (24)

120 (79)
31 (21)

0.636

≥50 w/out cancer

n, (%)
Total
n=10
6 (60)
4 (40)

P-value
0.186
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Table 16. Oral contraceptive use based on cohort (BRCA2)
≥50 w/
<50 w/ cancer
cancer
*
OCP Use
BRCA2

Yes
No
* Referent Group

n, (%)
Total n=46

n, (%)
Total n=60

P-value

34 (74)
12 (26)

49 (82)
11 (18)

0.337

≥50 w/out cancer
n, (%)
Total
n=8
7 (88)
1 (12)

P-value
0.407

Women with a BRCA1 or BRCA2 mutation who developed cancer at age 50
or older were more likely to have taken a hormone replacement therapy than
women who developed cancer prior to age 50. There was no difference in women
with a BRCA1 or BRCA2 mutation diagnosed at age 50 or older when compared to
those who had never developed cancer. The numbers and percentages of women
who used HRT are shown in tables 17-18.

Table 17. HRT use based on cohort (BRCA1)
≥50 w/
<50 w/ cancer
cancer
*
HRT Use
BRCA1

Yes
No
* Referent Group

n, (%)
Total n=36

n, (%)
Total n=118

P-value

20 (56)
16 (44)

20 (17)
98 (83)

<0.001

≥50 w/out cancer
n, (%)
Total
n=10
7 (70)
3 (30)

P-value
0.412
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Table 18. HRT use based on cohort (BRCA2)
≥50 w/
<50 w/ cancer
cancer
*
HRT Use
BRCA2

n, (%)
Total n=46

n, (%)
Total n=51

P-value

27 (59)
19 (41)

8 (16)
43 (84)

<0.001

Yes
No
* Referent Group

≥50 w/out cancer
n, (%)
Total
n=7
5 (71)
2 (29)

P-value
0.521

BMI
No statistically significant differences in mean BMI were found between
women diagnosed before age 50 and those diagnosed at age 50 or older with a
BRCA1 or BRCA2 mutation. There were also no statistically significant differences
between women diagnosed with cancer at age 50 or older and those with no cancer
diagnosis. The average BMI for each group, as well as p values, are shown in
Figure 7.

Figure 7. Average BMI and p-values, by age at diagnosis
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SCREENING FREQUENCY AND MODALITY
There was a statistically significant difference between the number of women
with a BRCA1 mutation who received mammograms when comparing those
diagnosed with cancer prior to age 50 and those who developed cancer at age 50
or older (p=0.009). Women who developed their cancer at a later age were more
likely to have undergone mammography than those who developed cancer at an
earlier age. There was no difference between women with a BRCA1 or BRCA2
mutation who developed cancer at age 50 or older and those who had never
developed cancer (p=0.448, 0.896). In women with a BRCA2 mutation, there was
no significant difference in whether or not the woman had received a mammogram
when comparing women who developed cancer prior to age 50 to those who
developed cancer at age 50 or older (p=0.535).
There was a statistically significant difference in women with a BRCA1 or
BRCA2 mutation who had received a breast MRI when comparing women who
developed cancer prior to age 50 to those who developed cancer at age 50 or older
(p=0.017, <0.001). Women diagnosed at age 50 or older were more likely to have
had a breast MRI than those who developed cancer before age 50. There was no
statistically significant difference in BRCA1 or BRCA2 positive women who
developed cancer at age 50 or older when compared to those with no cancer
diagnosis (p=0.095, 0.788).
Women with a BRCA1 mutation with no cancer development were less likely
to have had a clinical breast exam than those who had developed cancer at age 50
or older (p=0.003). There was no statistically significant difference between BRCA1
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and BRCA2 women diagnosed with cancer at an earlier age when compared to
those diagnosed at a younger age when observing whether or not they had a
clinical breast exam performed (p=0.585, 0.532). In addition, there was no
difference between BRCA2 women who developed cancer at age 50 or older when
compared to those who had no cancer (p=0.939).
There was no difference in the number of BRCA1 or BRCA2 positive women
who had had a CA-125 blood test when comparing those who developed cancer
prior to age 50 or those who had never developed cancer to women who developed
cancer at age 50 or older. P-value for BRCA1 positive women who developed
cancer prior to age 50 when compared to those who developed cancer at age 50 or
older was 0.378. When comparing those with a BRCA1 mutation who developed
cancer at age 50 or older to those who had never developed cancer, the p-value
was 0.252. In women with a BRCA2 mutation who developed cancer at a later age,
the p-value was 0.131 when compared to those who developed cancer at an earlier
age. The p-value when comparing women with a BRCA2 mutation who had never
developed cancer to those who had developed cancer at age 50 or older was 0.397.
There was no difference in the number of women with a BRCA1 or BRCA2
mutation who had had a transvaginal ultrasound when comparing women who
developed cancer at a later age to women who developed cancer at a younger age
or who had never had a cancer diagnosis (p=0.872, 0.103, 0.842, 0.726).
The percentage of women who underwent the different screening procedures
are shown in figures 8-9.
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Figure 8. Percentage of women undergoing screening procedures based on cohort
(BRCA1), by age at diagnosis
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Figure 9. Percentage of women undergoing screening procedures based on cohort
(BRCA2), by age at diagnosis
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There was no difference in the screening frequency when comparing women
with a BRCA1 or BRCA2 mutation diagnosed with cancer at age 50 or older to
those who had never developed cancer (p=0.738, 0.825). Women with a BRCA1 or
BRCA2 mutation who developed cancer at age 50 or older had a different
distribution of screening frequency when compared to women who developed
cancer prior to age 50 (p= 0.006, 0.009). The number of women who performed
screening at certain time intervals are shown in tables 19-20.

Table 19. Screening frequency based on cohort (BRCA1)
≥50 w/
<50 w/ cancer
cancer
*
Screening
Frequency
(BRCA1)
n, (%)
n, (%)
P-value
Total n=29 Total n=67
>Once per year
Annually
<Once per year
Never
* Referent Group

15 (52)
11 (38)
2 (7)
1 (3)

12 (18)
47 (70)
7 (10)
1 (2)

0.006

Table 20. Screening frequency based on cohort (BRCA2)
≥50 w/
<50 w/ cancer
Screening
cancer *
Frequency
(BRCA2)
n, (%)
n, (%)
P-value
Total n=39 Total n=34
>Once per year
Annually
<Once per year
Never
* Referent Group

16 (41)
20 (51)
3 (8)
0 (0)

3 (9)
24 (70)
5 (15)
2 (6)

0.009

≥50 w/out cancer
n, (%)
Total
n=11
6 (55)
5 (45)
0 (0)
0 (0)

P-value

0.738

≥50 w/out cancer
n, (%)
Total
n=7
3 (43)
3 (43)
1 (14)
0

P-value

0.825
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CHEMOPREVENTION USE
There was not enough data to determine the differences in tamoxifen use
between women with a BRCA1 or BRCA2 mutation who had developed cancer
before or at age 50 or older. This information was not available in the medical
records for the majority of these women. We did find that of the women who had
not developed cancer, 56% of BRCA1 positive women and 88% of BRCA2 positive
women had used tamoxifen.

RISK-REDUCING PROCEDURES
There was no difference in whether or not women with a BRCA1 mutation
underwent risk-reducing surgery when comparing women diagnosed at age 50 or
older to those diagnosed prior to age 50. Women with a BRCA2 mutation who
developed cancer under age 50 were more likely to undergo risk-reducing surgery
than those who developed cancer at age 50 or older. Women with a BRCA1 or
BRCA2 mutation who had no cancer history were more likely to have undergone
risk-reducing surgery than those who had developed cancer at age 50 or older. The
numbers and percentages of women who underwent risk-reducing mastectomy or
BSO are shown in tables 21-22.
The vast majority of women underwent risk-reducing BSO. Four women with
a BRCA1 mutation underwent a prophylactic mastectomy; three diagnosed prior to
age 50 and one diagnosed at age 50 or older. There were only two women who
underwent both a prophylactic bilateral mastectomy and BSO; both were over age
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50 with no cancer diagnosis, one of whom had a BRCA1 mutation and one who had
a BRCA2 mutation.

Table 21. Number of women who underwent risk-reducing mastectomy or BSO
based on cohort (BRCA1)
≥50 w/
<50 w/ cancer
≥50 w/out cancer
cancer *
Underwent
Surgery
n, (%)
(BRCA1)
n, (%)
n, (%)
P-value
Total
P-value
Total n=40 Total n=169
n=11
Yes
13 (32.5)
86 (51)
9 (82)
0.092
0.009
No
27 (67.5)
83 (49)
2 (18)
* Referent Group
Table 22. Number of women who underwent risk-reducing mastectomy or BSO
based on cohort (BRCA2)
≥50 w/
<50 w/ cancer
≥50 w/out cancer
cancer
*
Underwent
Surgery
n, (%)
(BRCA2)
n, (%)
n, (%)
P-value
Total
P-value
Total n=51 Total n=67
n=8
Yes
13 (25)
35 (52)
7 (87.5)
<0.001
0.003
No
38 (75)
32 (48)
1 (12.5)
* Referent Group

Women with a BRCA1 or BRCA2 mutation diagnosed with cancer under age
50 underwent risk-reducing surgeries at a statistically significant younger age than
those diagnosed at age 50 or older (p<0.0001 and 0.0149, respectively). There
was no difference between the age of risk-reducing surgery for women over 50 with
no cancer and those diagnosed at age 50 or older. The mean ages at risk-reducing
surgery and p-values are shown in tables 23-24.
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Table 23. Mean age at risk-reducing mastectomy or BSO based on cohort (BRCA1)
BRCA1
Mean (SD)
P-value
<50 w/ cancer
43.77 (7.01)
<0.0001
≥ 50 w/ cancer *
54.86 (12.03)
≥50 w/o cancer
51.78 (11.20)
0.5452
* Referent Group

Table 24. Mean age at risk-reducing mastectomy or BSO based on cohort (BRCA2)
BRCA2
Mean (SD)
P-value
<50 w/ cancer
45.32 (9.15)
0.0149
≥ 50 w/ cancer *
52.23 (6.06)
≥50 w/o cancer
53.57 (6.63)
0.6530
* Referent Group

TUMOR CHARACTERISTICS
There was no statistically significant difference in ER status among women
with a BRCA1 mutation who were diagnosed with breast cancer prior to age 50
when compared to those who developed breast cancer at age 50 or older. Women
with a BRCA2 mutation who developed cancer prior to age 50 were more likely to
have an ER positive breast cancer than those who developed cancer at age 50 or
older. The numbers of women with ER positive and ER negative breast tumors are
shown in tables 25-26.

Table 25. ER status based on cohort (BRCA1)
<50 w/ cancer
≥50 w/ cancer
n, (%)
n, (%)
BRCA1 Group
Total n=96
Total n=18
ER positive
24 (25)
8 (44)
ER negative
72 (75)
10 (56)

P-value
0.092
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Table 26. ER status based on cohort (BRCA2)
<50 w/ cancer
≥50 w/ cancer
BRCA2 Group
n, (%)
n, (%)
Total n=43
Total n=24
ER positive
33 (77)
9 (37)
ER negative
10 (23)
15 (63)

P-value
0.001

The PR status of breast tumors in women with a BRCA1 mutation who
developed breast cancer prior to age 50 was not statistically significant when
compared to women who developed breast cancer at age 50 or older. Women with
a BRCA2 mutation who developed cancer prior to age 50 were more likely to have a
PR positive breast cancer when compared to those with cancer at age 50 or older.
The numbers of women with PR positive and PR negative breast tumors are shown
in tables 27-29.

Table 27. PR status based on cohort (BRCA1)
<50 w/ cancer
≥50 w/ cancer
n, (%)
n, (%)
BRCA1 Group
Total n=92
Total n=17
PR positive
21 (23)
5 (29)
PR negative
71 (77)
12 (71)

Table 28. PR status based on cohort (BRCA2)
<50 w/ cancer
≥50 w/ cancer
BRCA2 Group
n, (%)
n, (%)
Total n=41
Total n=24
PR positive
31 (76)
7 (29)
PR negative
10 (24)
17 (71)

P-value
0.558

P-value
<0.001

There was no difference in the Her2/neu status when comparing women with
a BRCA1 or BRCA2 mutation diagnosed with cancer under age 50 to those
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diagnosed at age 50 or older. The numbers of women with Her2/neu positive and
Her2/neu negative breast tumors are presented in tables 29-30.

Table 29. Her2/neu status based on cohort (BRCA1)
<50 w/ cancer
≥50 w/ cancer
BRCA1 Group
n, (%)
n, (%)
Total n=72
Total n=14
Her2/neu positive
6 (8)
2 (14)
Her2/neu negative
66 (92)
12 (86)

Table 30. Her2/neu status based on cohort (BRCA2)
<50 w/ cancer
≥50 w/ cancer
n, (%)
BRCA2 Group
n, (%)
Total n=34
Total n=20
Her2/neu positive
6 (18)
1 (5)
Her2/neu negative
28 (82)
19 (95)

P-value
0.483

P-value
0.182

ETHNICITY
There was no difference in the ethnicity distribution when women with a
BRCA1 or BRCA2 mutation who developed cancer at age 50 or older were
compared to those who had never developed cancer. There was a statistically
significant difference in the distribution of ethnicity between women with a BRCA1
or BRCA2 mutation who developed cancer prior to age 50 when compared to
women who developed cancer at age 50 or older (p=0.006 for BRCA1 and p=0.019
for BRCA2). Ashkenazi Jewish women with a BRCA1 mutation are more likely to
have their cancer diagnosed at age 50 or older when compared to Caucasian
women with a BRCA1 mutation (p=0.002). In addition, women with a BRCA1
mutations whose race was listed as “other” were found to be more likely to have
their cancer diagnosed at age 50 or older when compared with Caucasian women
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(p=0.026). Hispanic women with a BRCA2 mutation were more likely to be
diagnosed with cancer prior to age 50 when compared to Caucasian women
(p=0.008).
The number and percentage of women from each ethnicity category are
shown based on their cohort in figures 10-11.

Figure 10. Ethnicity based on cohort (BRCA1), by age at diagnosis
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Figure 11. Ethnicity based on cohort (BRCA2), by age at diagnosis
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FAMILY HISTORY
For family history information, we collected data about first and second
degree relatives (FDR and SDR).
First Degree Relatives in BRCA1 Carriers
Women with a BRCA1 mutation diagnosed at age 50 or older were more
likely to have 0 or 1 affected first degree relative whereas those who had not
developed cancer were more likely to have 2 or 3 first degree relatives. We did not
find any statistically significant results when comparing the percentage of family
members diagnosed with a breast or ovarian cancer among the BRCA1 mutation
carriers.
The number of families and number and percentage of first degree relatives
with a breast or ovarian cancer diagnosis are shown in tables 31-32.

Table 31. First degree relatives with breast or ovarian cancer based on cohort
(BRCA1)
≥50 w/
Number of
<50 w/ cancer
≥50 w/out cancer
cancer
*
Families with N
cases of Breast
n, (%)
or Ovarian
n, (%)
n, (%)
Total
P-value
P-value
Cancer in FDR Total n=41 Total n=153
n=11
n=0
10 (24)
49 (32)
0 (0)
n=1
18 (44)
73 (48)
1 (9)
0.053
0.001
n=2
13 (32)
21 (14)
8 (73)
n=3
0 (0)
8 (5)
2 (18)
n≥4
0 (0)
2 (1)
0 (0)
* Referent Group
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Table 32. Percentage of first degree relatives with breast or ovarian cancer based
on cohort (BRCA1)
≥50 w/
Percentage of
<50 w/ cancer
≥50 w/out cancer
cancer *
FDRs with
Breast or
Ovarian
Cancers
0%
1-24%
25-49%
50-74%
100%
* Referent Group

n, (%)
Total n=41

n, (%)
Total n=153

P-value

10 (24)
17 (42)
11 (27)
0 (0)
3 (7)

49 (32)
48 (31)
24 (16)
12 (8)
20 (13)

0.094

n, (%)
Total
n=11
0 (0)
4 (36)
6 (55)
1 (9)
0 (0)

P-value

0.054

There was a statistically significant difference in whether or not a woman with
a BRCA1 mutation had first degree relatives diagnosed with breast or ovarian
cancer prior to age 50 when comparing women who developed cancer at age 50 or
older to those who had never had cancer (p=0.030). This data is shown in table 33.
We did not find any statistical significance when comparing whether or not each of
the groups had a first degree relative diagnosed with breast or ovarian cancer after
the age of 50. The number of women with first degree relatives diagnosed with
breast or ovarian cancer under age 50 and p-values are presented in table 33. The
number of women with first degree relatives diagnosed with breast or ovarian
cancer over the age of 50 and p-values are presented in table 34.
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Table 33. Cancer diagnoses <50 years of age in first degree relatives based on
cohort (BRCA1)
≥50 w/
First Degree
<50 w/ cancer
≥50 w/out cancer
cancer *
Relatives
Diagnosed
n, (%)
n, (%)
n, (%)
Under Age 50
Total
P-value
P-value
Total n=38 Total n=137
n=10
Yes
25 (66)
79 (58)
10 (100)
0.367
0.030
No
13 (34)
58 (42)
0 (0)
* Referent Group

Table 34. Cancer diagnoses ≥50 years of age in first degree relatives based on
cohort (BRCA1)
≥50 w/
<50 w/ cancer
≥50 w/out cancer
First Degree
cancer *
Relatives
n, (%)
Diagnosed ≥50
n, (%)
n, (%)
P-value
Total
P-value
Total n=38 Total n=121
n=11
Yes
14 (37)
37 (31)
3 (27)
0.471
0.557
No
24 (63)
84 (69)
8 (73)
* Referent Group

First Degree Relatives in BRCA2 Carriers
When comparing BRCA2 mutation carriers who developed cancer at age 50
or older to those who developed cancer prior to age 50, we found a statistically
significant difference between the number of first-degree relatives diagnosed with
breast or ovarian cancer. When we compared these data and looked at the
percentage of family members diagnosed with a breast or ovarian cancer, we still
found statistical significance between women with a BRCA2 mutation who
developed cancer prior to age 50 and those who developed cancer at age 50 or
older. The number of families and number and percentage of first degree relatives
with a breast or ovarian cancer diagnosis are shown in tables 35-36.
48

Table 35. Number of first-degree relatives with breast or ovarian cancer based on
cohort (BRCA2)
≥50 w/
Number of
<50 w/ cancer
≥50 w/out cancer
cancer *
Families with N
cases of Breast
or Ovarian
Cancer in FDR
n=0
n=1
n=2
n=3
n≥4
* Referent Group

n, (%)
Total n=49

n, (%)
Total n=66

P-value

10 (20)
29 (59)
8 (17)
1 (2)
1 (2)

35 (53)
21 (32)
7 (11)
3 (4)
0 (0)

0.005

n, (%)
Total
n=8
1 (12.5)
3 (37.5)
3 (37.5)
1 (12.5)
0 (0)

P-value

0.319

Table 36. Percentage of first degree relatives with breast or ovarian cancer
diagnosis based on cohort (BRCA2)
≥50 w/
Percentage of
<50 w/ cancer
≥50 w/out cancer
cancer *
Families with N
cases of Breast
or Ovarian
Cancer in FDR
0%
1-24%
25-49%
50-74%
100%
* Referent Group

n, (%)
Total n=49

n, (%)
Total n=66

P-value

10 (20)
24 (49)
9 (19)
2 (4)
4 (8)

35 (53)
12 (18)
7 (11)
4 (6)
8 (12)

0.001

n, (%)
Total
n=8
1 (12.5)
3 (37.5)
3 (37.5)
1 (12.5)
0 (0)

P-value

0.527

There was no difference between women with a BRCA2 mutation who
developed cancer at age 50 or older and those who developed cancer prior to age
50 when investigating whether they had any first degree relatives with a breast or
ovarian cancer diagnosis under age 50. We found statistical significance when
comparing BRCA2 mutation carriers who developed cancer prior to age 50 to those
who developed cancer at age 50 or older when comparing whether or not they had
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a first degree relative diagnosed with breast or ovarian cancer at age 50 or older.
The number of women with first degree relatives diagnosed with breast or ovarian
cancer under age 50 and p-values are presented in table 37. The number of
women with first degree relatives diagnosed with breast or ovarian cancer over the
age of 50 and p-values are presented in table 38.

Table 37. Cancer diagnoses <50 based on cohort (BRCA2)
≥50 w/
First Degree
<50 w/ cancer
≥50 w/out cancer
cancer *
Relatives
Diagnosed
n, (%)
n, (%)
n, (%)
Under Age 50
Total
P-value
P-value
Total n=43 Total n=58
n=5
Yes
17 (40)
26 (45)
3 (60)
0.595
0.380
No
26 (60)
32 (55)
2 (40)
* Referent Group

Table 38. Cancer diagnoses ≥50 based on cohort (BRCA2)
≥50 w/
<50 w/ cancer
≥50 w/out cancer
First Degree
cancer *
Relatives
n, (%)
Diagnosed ≥50
n, (%)
n, (%)
Total
P-value
P-value
Total n=44 Total n=54
n=7
Yes
26 (59)
7 (13)
4 (57)
<0.001
0.923
No
18 (41)
47 (87)
3 (43)
* Referent Group

Second Degree Relatives
When looking at second degree relatives who developed breast or ovarian
cancer, there was no difference between BRCA1 or BRCA2 positive women who
developed cancer prior to age 50 or had never developed cancer when compared to
those who developed cancer after the age of 50. The number of first-degree
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relatives with a breast or ovarian cancer and p-values are presented in tables 3940.

Table 39. Number of first degree and second degree relatives with breast or ovarian
cancer based on cohort (BRCA1)
≥50 w/
Number of
<50 w/ cancer
≥50 w/out cancer
cancer *
Families with N
cases of Breast
or Ovarian
Cancer in FDR
& SDR
n=0
n=1
n=2
n=3
n≥4
* Referent Group

n, (%)
Total n=41

n, (%)
Total n=163

2 (5)
13 (32)
15 (37)
6 (15)
5 (12)

19 (12)
51 (31)
47 (29)
33 (20)
13 (8)

P-value

n, (%)
Total
n=12

P-value

0.507

0 (0)
1 (8)
6 (50)
4 (34)
1 (8)

0.312

Table 40. Number of first degree and second degree relatives with breast or ovarian
cancer based on cohort (BRCA2)
≥50 w/
Number of
<50 w/ cancer
≥50 w/out cancer
cancer
*
Families with N
cases of Breast
n, (%)
or Ovarian
n, (%)
n, (%)
Total
P-value
P-value
Cancer in FDR Total n=49 Total n=70
n=8
& SDR
n=0
3 (6)
15 (21)
0 (0)
n=1
15 (31)
20 (29)
1 (12.5)
n=2
17 (35)
19 (27)
4 (50)
0.246
0.366
n=3
6 (12)
7 (10)
0 (0)
n≥4
8 (16)
9 (13)
3 (37.5)
* Referent Group
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DISCUSSION
To our knowledge, there has been no previous research specifically
evaluating the older population of women with a BRCA1 or BRCA2 mutation who do
not have cancer or who developed cancer at a later age (age 50 or older). The aim
of this study was to evaluate reproductive risk factors, family history, BMI, and
tumor pathology among women with a BRCA1 or BRCA2 mutation who developed
breast or ovarian cancer age 50 or older and determine if there were statistically
significant differences between any of these factors when compared to women with
a BRCA1 or BRCA2 mutation who developed cancer prior to age 50. An additional
aim of this study was to evaluate reproductive risk factors, family history, BMI, and
tumor pathology among women with a BRCA1 or BRCA2 mutation who are over the
age of 50 and have not developed cancer and determine if there were any
significant differences in these factors when compared to women with a BRCA1 or
BRCA2 mutation who developed cancer at age 50 or older. The goal of the
analyses was to determine whether or not there are factors in BRCA1 or BRCA2
positive women that determine whether a woman develops early or late onset
breast cancer as well as to determine whether there are factors that determine
whether or not a woman with a BRCA1 or BRCA2 mutation ever develops breast or
ovarian cancer.
Women with a BRCA1 or BRCA2 mutation who developed cancer prior to
age 50 were more likely to develop breast cancer as their first cancer diagnosis
than those who developed cancer at age 50 or older. The vast majority of women
diagnosed under age 50 (79% of BRCA1 and 96% of BRCA2 mutation carriers)
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were diagnosed with breast cancer whereas only 42% of BRCA1 and 53% of
BRCA2 mutation carriers diagnosed at age 50 or older were diagnosed with breast
cancer. Ovarian cancer was more likely to be diagnosed in the women who
developed cancer at age 50 or older than those who developed cancer prior to age
50. The fact that women are more likely to be diagnosed with ovarian cancer at age
50 or older is consistent with the literature, as ovarian cancer often develops at an
older age (6, 61), however it is interesting to note that women who developed
cancer at age 50 or older were had an approximately equal likelihood to develop
ovarian cancer as they did to develop breast cancer. In women with a BRCA1 or
BRCA2 mutation, the lifetime risk of breast cancer is greater than that of ovarian
cancer (3-6, 61), however from this study, it appears as though at age 50 or older,
the chance for a woman with a BRCA1 or BRCA2 mutation to develop breast
cancer is approximately the same as that to develop ovarian cancer.

REPRODUCTIVE RISK FACTORS
Age at Menarche
Age at menarche did not show statistical significance between any of the
groups in our study. This is consistent with one previous study that did not find an
association between age at menarche and breast cancer risk in BRCA1 or BRCA2
carriers (10). Other studies have found that a later age of menarche is associated
with a decreased breast cancer risk in BRCA1 mutation carriers (9, 15), however
this was not observed in our population. Our study suggests that the age at
menarche does not affect whether or not a woman with a BRCA1 or BRCA2
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mutation will develop breast or ovarian cancer before age or after age 50. It also
suggests that age at menarche does not determine whether a woman will develop
cancer at age 50 or older or not develop cancer at all.

Age at Menopause
Women with a BRCA1 or BRCA2 mutation who developed cancer prior to
age 50 underwent menopause at a statistically significant younger age than women
who developed cancer at age 50 or older. Those with a BRCA1 mutation who
developed cancer at age 50 or older underwent menopause at an average age of
44 years and those who developed cancer after 50 underwent menopause at an
average age of 49. This is not consistent with current literature. Early age at
menopause is associated with a decreased risk of breast and ovarian cancer (7, 10,
12). We would expect that women diagnosed with cancer at age 50 or older would
have an earlier age of menopause. The reason for the difference in our study is
likely that women diagnosed under age 50 underwent menopause earlier due to
chemotherapy or surgery. When observing age at prophylactic surgery, women
diagnosed with cancer at a younger age were more likely to undergo prophylactic
BSO at a younger age when compared to those who developed cancer at a later
age. When ascertaining the age at menopause, we did not distinguish between
women who had naturally undergone menopause from women whose menopause
was surgically or chemotherapy induced. This likely accounts for the difference
seen in ages at menopause between women diagnosed with cancer at a younger
age. Because these women were more likely to have undergone chemotherapy or
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surgery that induced menopause, these women went through menopause at a
statistically significant younger age. Future studies should investigate whether the
natural age at menopause differs between women who developed cancer at a late
vs. early age or those who have not developed cancer.
Women with a BRCA1 mutation who developed cancer at age 50 or older
went through menopause at an average age of 49 while those who had never
developed cancer underwent menopause at an average age of 44. Women who
developed cancer at a later age underwent menopause at a statistically significant
older age than those with no cancer diagnosis. This is not consistent with the
current literature. It is not known why this difference was seen in BRCA1 mutation
carriers, but not in BRCA2 mutation carriers. In BRCA2 carriers, the average age at
menopause in women who developed cancer at age 50 or older was 49 and those
who had never developed cancer underwent menopause at an average age of 50.
This is more consistent with the current literature. We are unable to explain the
difference in age at menopause between BRCA1 mutation carriers whose cancer
developed at age 50 or older and those who had never developed cancer. This is a
factor that needs further investigation.

Age at First Full-Term Pregnancy
Age at first full-term pregnancy did not appear to have an effect on whether a
woman with a BRCA1 or BRCA2 mutation had early or late onset cancer. It also did
not appear to have an effect on whether or not a woman with a BRCA1 or BRCA2
mutation developed cancer at age 50 or older or had never developed cancer. The
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literature about age at first full-term pregnancy in women with a BRCA1 or BRCA2
mutation is not consistent. Some studies have found that early age at full-term birth
was not protective against breast cancer in women with a BRCA1 or BRCA2
mutation (14). Other studies have shown that later ages of first childbirth was
associated with an increased risk of breast cancer in BRCA2 mutation carriers (15).
Our study did not find any statistically significant differences between the groups,
suggesting that age at first full-term pregnancy does not significantly affect whether
or not a woman will develop cancer at an early or later age or whether she will
develop cancer during her lifetime.

Parity
Women with a BRCA1 mutation who developed cancer at age 50 or older
had more children (2.73) than those who developed cancer prior to age 50 (1.96)
and Women with a BRCA2 mutation who developed cancer at age 50 or older had
more children (2.33) than those who developed cancer prior to age 50 (1.86). While
these results were not statistically significant, they did approach significance for
individuals with a BRCA1 mutation (p=0.0710 for BRCA1 and p=0.595 for BRCA2).
Previous studies have found that the risk for breast and ovarian cancer in women
with a BRCA1/2 mutation decreases as parity increases (9, 15-17), however we did
not find any statistical significance in our data. We did not find any differences in
parous and non-parous women with a BRCA1 or BRCA2 mutation who developed
cancer at age 50 or older when compared to those who developed cancer prior to
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age 50 or who had never developed cancer. This has been seen in previous
studies (15).
There was a woman with a BRCA1 mutation diagnosed at age 50 or older
who had 10 children. Because of the possibility of skewed data, we analyzed parity
in such a way that those with four or more children were put into one group. When
we attempted to correct for this possibility of skewed data, there was no statistical
significance between any of the groups and the p-values did not approach
significance. Parity does not appear to have an effect on whether or not a woman
with a BRCA1 or BRCA2 mutation will develop cancer at an earlier or later age. It
also does not seem to have an effect on whether a woman develops cancer at age
50 or older or does not develop cancer. Because we saw statistically significant
values or values approaching significance when looking at total parity for the
groups, it may be that having many children (more than 4) has an effect on breast
or ovarian cancer risk, however the data may be skewed in our analysis.

Breastfeeding
There was no statistical difference in the mean time of breastfeeding among
BRCA1 or BRCA2 mutation carriers who developed cancer prior to age 50 when
compared to those who developed cancer at age 50 or older. There was also no
difference in women who had never developed cancer when compared to those
who developed cancer at age 50 or older. We also investigated whether there was
a difference in any of the groups when comparing whether or not they had ever
breastfed at all and found no significance between any of the groups. From our
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study, it does not appear that breastfeeding has an impact on the breast or ovarian
cancer risk in women with a BRCA1 or BRCA2 mutation. This is consistent with
previous studies (9, 11, 15, 18).

Overall Reproductive Factors
Many of the reproductive factors that are known to have an effect on a
woman’s breast or ovarian cancer risk do not seem to have an effect on this risk in
BRCA1 or BRCA2 mutation carriers. Parity may have some effect, however it
seems as though this effect may only be evident if a woman has more than 4
children. The fact that reproductive factors do not appear to have an effect on
whether a woman is diagnosed with cancer at an early or later age likely means that
the woman’s risk from her BRCA1 or BRCA2 mutation overrides any protective
effect that reproductive factors may have.

OCP AND HRT USE
We did not find any difference in whether or not a woman had used oral
contraceptives when comparing women who developed cancer at age 50 or older to
those who developed cancer before age 50 or had never developed cancer. It does
not appear, from our study, that oral contraceptive use affects breast or ovarian
cancer development in BRCA1 or BRCA2 mutation carriers.
We found that women who developed cancer at age 50 or older were more
likely to have used hormone replacement therapy than women who developed
cancer prior to age 50. This is likely due to the ascertainment of the two groups.
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Most of the women who developed cancer under age 50 had not yet gone through
menopause, therefore they were less likely to have needed hormone replacement
therapy. No conclusions can be drawn about hormone replacement therapy use
and breast and ovarian cancer development from this data.

BMI
While there were no statistically significant differences in women with a
BRCA1 or BRCA2 mutation who developed cancer at age 50 or older when
compared to those who developed cancer prior to age 50 or had never developed
cancer, we did note that women who were over age 50 with no cancer diagnosis
had a lower average BMI than the other groups. While this difference was not
statistically significant, it was consistent among the BRCA1 and BRCA2 groups.
Previous literature has shown that women in the general population with a lower
BMI after menopause have a decreased risk of breast cancer (27, 28). For this
study, BMI was ascertained at the time the individual presented to MD Anderson for
their genetic testing. Women diagnosed at a younger age may have had their
genetic testing performed at a younger age compared to women who were
diagnosed at an older age, therefore the data may be somewhat biased. A
woman’s body weight fluctuation throughout life may have more impact on her
breast cancer diagnosis than BMI at a specific time in her life (29, 62), therefore a
more accurate way to assess whether BMI impacts breast or ovarian cancer may be
to record a woman’s BMI at different time points in her life.
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SCREENING
We observed screening frequency and screening modalities of women with a
BRCA1 or BRCA2 mutation prior to their cancer diagnosis. In looking at screening
frequency, we found a difference in frequency of screening when comparing women
with a BRCA1 or BRCA2 mutation who developed cancer at age 50 or older to
those who developed cancer prior to age 50. Women who developed cancer at age
50 or older underwent more frequent screening than those who developed cancer
prior to age 50. This is likely because many of the women who were diagnosed
under age 50 were diagnosed prior to 40 years of age and the breast cancer
screening recommendations for women in the general population is to begin
mammography at age 40. Because many of these women were not yet 40 years of
age, it is likely that their first mammogram was for diagnostic purposes, not for
screening purposes. In addition, some of the women who developed cancer under
age 50 may not have had knowledge of their BRCA mutation prior to their cancer
diagnosis, so they were likely not undergoing the increased surveillance
recommendations that have been developed for women with a BRCA1 or BRCA2
mutation. Women who developed cancer at age 50 or older were likely already
getting their annual breast cancer screening, even without knowledge of their BRCA
mutation, due to the screening recommendations that are in place for the general
population.
There was no difference in screening frequency between women who
developed breast cancer at age 50 or older and those who had never developed
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cancer. This is likely because these women are following current medical
recommendations to undergo screening annually since they are over the age of 40.
When looking specifically at mammography screening, we found that women
with a BRCA1 mutation who developed cancer at age 50 or older were more likely
to have had a mammogram when compared to those who developed cancer prior to
age 50. Again, this is quite likely due to current breast cancer screening for the
general population and younger women most likely received their first mammogram
for diagnostic purposes. We did not see this difference in BRCA2 mutation carriers.
We cannot explain the difference between these two groups.
In women with a BRCA1 or BRCA2 mutation who developed cancer at age
50 or older, we found that they were more likely to have had a breast MRI than
women who developed cancer prior to age 50. This was an interesting result given
that breast MRI is recommended to all women with a BRCA mutation. It is possible
that women who developed cancer at age 50 or older may have known about their
BRCA mutation prior to developing cancer and began screening recommendations
for that population whereas those who developed cancer prior to age 50 may have
not had knowledge of their BRCA mutation prior to developing their own cancer and
had not received screening recommendations for BRCA carriers. Women who
developed their cancer later in life are more likely to have had other family members
diagnosed with cancer, given the older ages of their relatives, and therefore may
have had knowledge of their BRCA mutation, or may have been receiving breast
MRIs due to their family history, prior to their own cancer diagnosis.
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We found that BRCA1 carriers with no cancer were less likely to have had a
clinical breast exam when compared to those who developed cancer at age 50 or
older. Women undergoing more screening are more likely to have a breast cancer
diagnosis because the cancer may be detected by screening. This same
difference, however, was not seen in BRCA2 mutation carriers; there was no
difference when comparing those who developed cancer at age 50 or older to those
with no cancer diagnosis. We found no difference in the proportion of women who
had received a clinical breast exam when comparing those diagnosed at age 50 or
older to those who were diagnosed before age 50.
We found no difference in the proportion of women undergoing ovarian
cancer screening (CA-125 blood test or transvaginal ultrasound) when comparing
those who developed cancer prior to age 50 and those who developed cancer at
age 50 or older. In addition, there was no difference in the proportion of women
undergoing ovarian cancer screening when comparing those who developed cancer
at age 50 or older and those who had never developed cancer.

CHEMOPREVENTION USE
We were unable to analyze data comparing the use of chemopreventive
agents among the groups. Chemoprevention use was not mentioned in the majority
of the medical records for women who had a cancer diagnosis. In women who had
not had a cancer diagnosis we found that 56% of BRCA1 carriers and 88% of
BRCA2 carriers had used tamoxifen. The use of tamoxifen in BRCA1 mutation
carriers may be less than BRCA2 carriers because it is known that BRCA1 positive
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women are more likely to have a triple-negative (ER/PR/Her2/neu status) breast
cancer and tamoxifen is not protective against triple-negative breast cancers.
Women with a BRCA1 mutation may feel as though tamoxifen is not as effective
against breast cancer as it is in the general population, so fewer women may
choose to use it. In addition, it has been previously reported that women are
concerned about the side effects of tamoxifen, leading some women to decline its
use as a chemopreventive agent (63).

RISK-REDUCING SURGERIES
Women with a BRCA1 or BRCA2 mutation who developed cancer prior to
age 50 underwent prophylactic surgeries at a statistically significant younger age
than those who developed cancer at age 50 or older. Studies have found that the
median time to risk-reducing surgery is approximately four months after learning
about a positive BRCA result (64). Women who developed cancer under age 50
likely found out about their BRCA status earlier than those who developed cancer at
age 50 or older and, therefore, underwent their risk-reducing surgery at an earlier
age.
We found that women over age 50 with no cancer diagnosis were more likely
to have undergone a risk-reducing surgery than those who had developed cancer at
age 50 or older. This is expected because these women have not developed
cancer and it is likely that this is due to their risk-reducing surgery. Risk-reducing
BSO reduces breast cancer risk by approximately 50% and ovarian cancer by up to
96% (37, 38, 41-43). However, the average age that women over age 50 with no
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cancer diagnosis underwent their risk-reducing surgery was 51.78 in BRCA1
mutation carriers and 53.78 in BRCA2 mutation carriers. They did not undergo
surgery at a younger age than women who developed cancer at age 50 or older.
When comparing average age at diagnosis and average age of surgery, it is
interesting to note that women who developed cancer prior to age 50 appear to
have undergone risk-reducing surgery after their cancer diagnosis and women who
developed cancer at age 50 or older seem to have undergone risk-reducing surgery
prior to developing their first cancer. This may be due to the risk-reducing surgery
delaying the development of cancer in these individuals. From this observation, it
seems as though women diagnosed with cancer will undergo a risk-reducing
surgery sooner than those with no cancer diagnosis, however this may also be due
to these women finding out about their BRCA status at a younger age as well. In
our study, in each of the groups of women over the age of 50, they underwent their
surgeries at a similar age. It appears as though with no cancer diagnosis, women
will wait until a later age to pursue risk-reducing surgery, however it does not seem
as though a cancer diagnosis impacts their decision. It is likely that the woman’s
family history of cancer, knowledge of cancer risks, knowledge of BRCA status, and
recommendations from physicians impact her decision to undergo risk-reducing
procedures.
There was no difference in the age at risk-reducing surgery among BRCA1
or BRCA2 women who developed cancer at age 50 or older when compared to
those who had never had a cancer diagnosis. Again, it appears as though the
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cancer diagnosis in the women diagnosed at a younger age probably impacts their
decision to undergo risk-reducing surgery at a younger age.
There were only three women over the age of 50 who had not developed
cancer that had never undergone any risk-reducing surgeries. These women were
last seen at MD Anderson at ages 51, 53, and 82. Because of the small number of
women who have not undergone risk-reducing surgeries, it is difficult to draw
conclusions about some of the findings when comparing women who developed
cancer at age 50 or older to those who have never developed cancer. The other
women in this category may have developed cancer if it were not for their riskreducing surgeries. While risk-reducing surgeries are not 100% preventive, it is
known that bilateral mastectomy reduces the breast cancer risk by 90% (41) and
BSO reduces breast cancer risk by 50% and ovarian cancer risk by up to 96% (37,
38, 42, 43). The majority of women who underwent risk-reducing surgery did not
undergo bilateral mastectomy, so they do still have a risk to develop breast cancer.

TUMOR CHARACTERISTICS
We found that women with a BRCA2 mutation who developed cancer at age
50 or older were more likely to have an ER/PR negative breast cancer than those
who developed breast cancer prior to age 50. While women with early-onset breast
cancer are more likely to have ER/PR negative tumors than women with later-onset
breast cancer, one study did find that BRCA2 mutation carriers whose cancer was
diagnosed at a later age were more likely to have ER/PR negative tumors (47). The
reason for this finding is unknown at this time and more research about women with
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BRCA2 mutations and ER/PR negative tumors is warranted as this may lead to
clinical implications when discussing endocrine therapies for breast cancer.
There was no difference in ER or PR status in women with a BRCA1
mutation when comparing those who developed cancer prior to age 50 to those who
developed cancer at age 50 or older. This is likely because women with a BRCA1
mutation are more likely to have a triple-negative breast cancer, therefore women
with early or late onset breast cancer do not differ significantly in their ER/PR status.
We did not find a difference in Her2/neu status when comparing women with
a BRCA1 or BRCA2 diagnosed prior to age 50 to those diagnosed at age 50 or
older. In the study by Atchley et al, (47) they found that women with a BRCA2
mutation with later-onset breast cancer were more likely to have Her-2/neu negative
breast cancers. In our study, there was no statistically significant difference in Her2/neu status in women diagnosed before age 50 and those diagnosed at age 50 or
older.

ETHNICITY
We identified a difference in the ethnicity distribution in both BRCA1 and
BRCA2 mutation carriers when comparing women who developed cancer prior to
age 50 to those who developed cancer at age 50 or older. From our data, it
appears as though Ashkenazi Jewish women and women of “other” race develop
cancer at an older age when compared to other ethnicities. It also appears as
though Hispanic women with a BRCA2 mutation develop cancer at a younger age
when compared to other ethnicities. The majority of the women included in our
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study were Caucasian, therefore it would be beneficial to look at these populations
in greater numbers to determine whether there is a significant difference in their
cancer risks based on ethnicity. To our knowledge, there have been no published
reports about early vs. late cancer diagnosis in BRCA1 or BRCA2 mutation carriers
among different ethnicities.

FAMILY HISTORY
We found that women over the age of 50 with no cancer diagnosis were
more likely to have 2 or 3 first-degree relatives diagnosed with a breast or ovarian
cancer while those diagnosed with cancer at age 50 or older were more likely to
have 0 or 1 relative with a breast or ovarian cancer diagnosis. Women with no
breast cancer were more likely to have undergone a risk-reducing surgery than
those who had developed breast cancer at age 50 or older and this may be due to
having seen more relatives affected with a breast or ovarian cancer or having prior
knowledge of a BRCA mutation in the family. While the p-value approached
significance (p=0.054), we did not identify any statistical significance between these
groups when looking at the percentage of first-degree relatives diagnosed with a
breast or ovarian cancer.
All of the women with a BRCA1 mutation in our study who had not developed
cancer had at least one first-degree relative who developed breast or ovarian
cancer prior to age 50. This was statistically different than the group of women who
developed cancer at age 50 or older. We found that 66% of women diagnosed with
cancer at age 50 or older had a first-degree relative who was diagnosed with breast
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or ovarian cancer before 50 years of age and 34% of them did not have a firstdegree relative diagnosed under age 50. From this data, it appears as though
women with no cancer have more early-onset breast and/or ovarian cancer in their
first-degree relatives, however the majority of the women with no cancer had a riskreducing surgery. It is likely that these women underwent their surgery due to many
family members having a breast or ovarian cancer diagnosis or may be due to prior
knowledge of a BRCA mutation in the family.
Women who developed cancer prior to age 50 were not more likely to have a
first-degree relative diagnosed under age 50 when compared to the group of
women who developed cancer at age 50 or older. From this information, it does not
appear that early-onset breast cancer in a first-degree relative predicts early-onset
breast cancer in another first-degree relative. Likewise, it does not appear that
having a first-degree relative with cancer diagnosed at age 50 or older predicts
later-age of cancer onset in women with a BRCA1 mutation. When comparing
women with cancer at age 50 or older to those diagnosed before 50 or those who
had not had a cancer diagnosis, there was no difference in whether or not they had
a first-degree relative diagnosed with breast or ovarian cancer at age 50 or older.
Women with a BRCA2 mutation who developed cancer before age 50 were
more likely to have no breast or ovarian cancer diagnoses in their first-degree
relatives when compared to women who developed cancer at age 50 or older.
When we looked at the percentage of first-degree relatives with a cancer diagnosis,
we found that women who developed cancer before age 50 were more likely to
have 0% of their relatives affected with breast cancer while those who developed
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cancer at age 50 or older were more likely to have 1-25% of their first-degree
relatives affected. These results may likely be due to the ages of first-degree
relatives in the family because women under age 50 may have younger relatives
than those who developed cancer at age 50 or later. Women over age 50 are more
likely to have more relatives that are of older ages when compared to the women
who developed cancer under age 50. Because age is a risk factor for breast and
ovarian cancer, it may be that the first-degree relatives of women who had cancer
under age 50 have not yet developed cancer but may have a cancer diagnosis in
the future. This result is likely due to ascertainment bias.
Women with a BRCA2 mutation who developed cancer at age 50 or older did
not differ in the number or percentage of family members with breast or ovarian
cancer when compared to women who had not developed cancer. From this data, it
does not appear that the number of family members with a cancer diagnosis affects
the chance that a woman will develop cancer.
There was no difference between women with a BRCA2 mutation who
developed cancer at age 50 or older and those who developed cancer prior to age
50 when investigating whether they had any first degree relatives with a breast or
ovarian cancer diagnosis under age 50. Similarly, we did not find any difference in
whether or not a woman had a first-degree relative with breast or ovarian cancer
under 50 when comparing women who developed cancer at age 50 or older to
those who had never developed cancer. It does not appear that having a firstdegree relative with a cancer diagnosis under age 50 increases the risk for earlyonset breast or ovarian cancer in women with a BRCA2 mutation.
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We found that women with a BRCA2 mutation who developed cancer at age
50 or older were more likely to have a first-degree relative diagnosed with cancer at
age 50 or older when compared to women who developed cancer prior to age 50.
This trend may be present for two different reasons. Women with a history of lateronset breast cancer may develop later-onset breast cancer themselves or it may be
that women who developed cancer before age 50 have fewer first-degree relatives
over the age of 50 and, therefore, are less likely to have cancer diagnosed at age
50 or older. This finding may be due to ascertainment bias, therefore more studies
on age at diagnosis in family members may be warranted.
When combining first- and second-degree family members’ cancer histories,
it does not appear that there is any significant difference between any of the groups.
It does not appear that the number of first- and second-degree relatives with a
cancer diagnosis has an impact on early vs. late cancer diagnosis in women with a
BRCA1 or BRCA2 mutation. From our study, it is not evident that the age of onset
within a family with a BRCA1 or BRCA2 mutation can predict the age of onset for
other individuals within the family.

SUMMARY OF ASSOCIATIONS
Among our population of women with a BRCA1 or BRCA2 mutation we
identified several significant and interesting observations. We found that women
who developed their first cancer at or after age 50 appear to have an approximately
equal chance to develop ovarian cancer as they do to develop breast cancer. We
also found that reproductive risk factors and BMI do not appear to play a significant
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role in the development of breast or ovarian cancer among these women, however
further studies on the effect of age at menopause should be performed. Women
with a BRCA2 mutation who developed breast cancer at or after age 50 were more
likely to have an ER/PR negative tumors than those who developed their breast
cancer prior to age 50. Ethnicity may play a role in the development of early vs. late
onset of breast or ovarian cancer. Women of Ashkenazi Jewish descent with a
BRCA1 mutation appear to be more likely to develop late-onset breast or ovarian
cancer, whereas Hispanic women with a BRCA2 mutation seem to be more likely to
have an early-onset of breast or ovarian cancer. Family history of breast and
ovarian cancer may have an impact on the development of these cancers in an
individual, however this is not clear in our study and additional investigation on this
topic is warranted.

STUDY LIMITATIONS
There have been several limitations of the current study noted. The main
limitation to our study is ascertainment bias. All of the women included in this study
were patients at MD Anderson and, therefore, they likely either had a diagnosis of
breast or ovarian cancer or had a relative with breast or ovarian cancer. Therefore,
our population is highly skewed toward women who have a family history of cancer
or have had a breast or ovarian cancer diagnosis. In addition, our study only
included women who have knowledge of their BRCA mutation, so we were unable
to evaluate factors among women who have a BRCA mutation but do not have
knowledge of their BRCA status. This information would have likely been very
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helpful when studying reproductive risk factors, however would likely not play a
significant role when exploring screening frequencies/modalities and risk-reduction
surgeries.
Because this was a retrospective study, we were unable to obtain all relevant
information on every patient. In identifying some factors, there was information
missing on certain individuals. It is possible that this information would lead us to
find some significance in our analyses, however it is unlikely that this missing
information would alter the analyses a significant amount.
Another limitation to our study is that the family history information obtained
was via patient report and was not validated using medical records. It is possible
that some cancer diagnoses were misreported or under-reported due to patients not
recalling certain cancer diagnoses or recalling cancer diagnoses that did not truly
exist.
An additional limitation to this study is that we are unable to predict whether
the women who have not yet developed cancer will develop cancer in the future.
The average age of women with no cancer diagnosis in this study was 59.5 and
56.88 in BRCA1 and BRCA2 mutation carriers, respectively. These women may
still develop cancer in their lifetime, however we cannot predict whether or not they
will develop cancer, so this is a limitation in that we do not know which women will
go on to develop cancer or when they will develop it. Some women in this group
may be more similar to women diagnosed with cancer at age 50 or older, however
we are not able to ascertain which individuals may develop cancer.
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Only those women who underwent risk-reducing bilateral mastectomy were
recorded. Women who underwent a unilateral prophylactic mastectomy following a
breast cancer diagnosis in the contralateral breast were not recorded as having a
prophylactic mastectomy. Because we were interested in the age at the first breast
or ovarian cancer diagnosis, we did not feel it was necessary as the prophylactic
mastectomy was part of the treatment for the cancer in the contralateral breast.
There were no cases where a unilateral mastectomy was performed without a
breast cancer diagnosis.
We did not analyze the date at which a woman underwent BRCA mutation
analysis and at what age she learned of her BRCA1/2 mutation status. This
information would be beneficial in order to determine whether women underwent
risk-reducing surgeries prior learning of their BRCA status or if they were more likely
to undergo risk-reducing surgeries after a cancer diagnosis.

IMPLICATIONS AND FUTURE RESEARCH
The further characterization of women with a BRCA1 or BRCA2 mutation
who do not develop early-onset breast or ovarian cancer may aid in determining
what factors are important in early vs. late-onset breast or ovarian cancer
development. A larger cohort of BRCA1 and BRCA2 mutation carriers with no
cancer diagnosis prior to age 50 would be beneficial to determine whether or not the
results are consistent with those in this study. Additional research may also include
investigating when a woman received knowledge of her BRCA1 or BRCA2 mutation
and investigating whether this knowledge delays or prevents a cancer diagnosis,
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perhaps through a prospective study. Because there have not been any reports on
BRCA1 or BRCA2 carriers with later-onset breast or ovarian cancer, confirmation of
the results from this study as well as additional analyses in another population
would be valuable. In addition to further exploring the factors included in this study,
research on the effect of possible modifier genes and their role in early or late
development of breast and ovarian cancer may also be advantageous.
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